NASDAQ$HCAT
Health Catalyst Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Achieved strong performance exceeding quarterly guidance for revenue and Adjusted EBITDA.
Health Catalyst reported strong third-quarter results, exceeding the midpoint of their quarterly guidance for both revenue and Adjusted EBITDA. The company also hosted its annual Healthcare Analytics Summit conference in September, with over 3,000 registrants.
- Total revenue for the quarter was $61.737 million, a 31% increase year-over-year.
- Technology revenue was $38.262 million, a 37% increase year-over-year.
- Professional services revenue was $23.475 million, a 22% increase year-over-year.
- Adjusted EBITDA was $(5.794) million, compared to $(6.434) million in the same quarter last year.
Headline financials
Revenue & EPS history
Health Catalyst · Revenue · Quarterly
$61.7M
Revenue by segment
Health Catalyst · $61.7M total across 2 segments · Q3 2021
- Technology$38.3M+36.8%62.0%
- Professional Services$23.5M+22.1%38.0%
Forward guidance
For the fourth quarter of 2021, Health Catalyst expects total revenue between $61.4 million and $64.4 million, and Adjusted EBITDA between $(7.5) million and $(5.5) million. For the full year of 2021, the company expects total revenue between $238.6 million and $241.6 million, and Adjusted EBITDA between $(12.5) million and $(10.5) million.
Tailwinds
- Total revenue between $61.4 million and $64.4 million for Q4 2021
- Adjusted EBITDA between $(7.5) million and $(5.5) million for Q4 2021
- Total revenue between $238.6 million and $241.6 million for the full year 2021
- Adjusted EBITDA between $(12.5) million and $(10.5) million for the full year 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-3.1%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-4.0%
Avg return
30 days after
41%
11 / 27 earnings
Positive
+27.3%
Q2 2024
Best reaction
-36.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.9% | -21.7% | +4.6% | |
| Q4 2025 | -26.3% | -35.2% | -44.4% | |
| Q3 2025 | -5.6% | -20.5% | -10.2% | |
| Q1 2025 | +5.3% | +8.1% | +3.3% | |
| Q4 2024 | -11.1% | -8.5% | -7.9% | |
| Q3 2024 | +14.2% | +7.2% | +7.6% | |
| Q2 2024 | +27.3% | +7.3% | +22.9% | |
| Q1 2024 | -3.6% | +2.9% | -2.3% | |
| Q4 2023 | -14.7% | -8.9% | -14.4% | |
| Q3 2023 | +5.1% | -0.4% | +5.3% | |
| Q2 2023 | -8.0% | -5.0% | -12.4% | |
| Q1 2023 | -18.9% | -14.8% | -4.3% | |
| Q4 2022 | +7.3% | +5.8% | -14.8% | |
| Q3 2022 | +16.2% | +42.9% | +59.2% | |
| Q2 2022 | -36.6% | -34.7% | -35.9% | |
| Q1 2022 | -2.6% | +24.6% | +10.5% | |
| Q4 2021 | +1.5% | -7.1% | -3.7% | |
| Q3 2021 | -6.2% | -6.1% | -26.9% | |
| Q2 2021 | +1.5% | -2.3% | -2.8% | |
| Q1 2021 | -2.3% | -8.6% | -2.4% | |
| Q4 2020 | +0.6% | +0.1% | -2.1% | |
| Q3 2020 | -0.2% | -3.5% | +6.2% | |
| Q2 2020 | -7.2% | -10.9% | -3.4% | |
| Q1 2020 | -1.9% | -0.5% | -5.0% | |
| Q4 2019 | +1.3% | -5.8% | -20.1% | |
| Q3 2019 | +1.9% | -0.8% | -1.1% | |
| Q2 2019 | -11.5% | -7.8% | -13.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro